Compounders Research Compare

Achieve Life Sciences, Inc.(ACHV)

Biotechnology · Bothell, WA

$7.03+0.02 (+0.29%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Bothell, WA

28 employees

www.achievelifesciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Andrew D. Goldberg

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T22:50:18.828Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:50:18.828Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 721,692,770
Total debt · period ending 2026-06-30: 14,948,000
Cash · period ending 2026-06-30: 47,958,000
TTM operating income · period ending 2026-06-30: -58,278,000

FMP input reference: c295c1623f78bdf77a886cf07ea1e6d336f06da24b8c95eb76ef4971c7c9c79e

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ACHV EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

ACHV Competitors' EV/EBIT Ratio

Achieve Life Sciences, Inc.

Current

Market Cap

$721.69M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Candel Therapeutics, Inc.

Market Cap

$723.18M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Avalo Therapeutics, Inc.

Market Cap

$714.37M

EV/EBIT Ratio

N/A

TTM Avg

877.08x

3Y Avg

871.89x

5Y Avg

871.89x

Collegium Pharmaceutical, Inc.

Market Cap

$709.65M

EV/EBIT Ratio

9.07x

TTM Avg

12.78x

3Y Avg

12.26x

5Y Avg

15.40x

ArriVent BioPharma, Inc.

Market Cap

$702.82M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Apnimed, Inc.

Market Cap

$742.70M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Design Therapeutics, Inc.

Market Cap

$747.61M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cytek Biosciences, Inc.

Market Cap

$694.79M

EV/EBIT Ratio

N/A

TTM Avg

501.20x

3Y Avg

422.57x

5Y Avg

422.57x

Wave Life Sciences Ltd.

Market Cap

$693.61M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Faeth Therapeutics, Inc.

Market Cap

$693.19M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Achieve Life Sciences, Inc. (ACHV)	$721.69M	N/A	N/A	N/A	N/A
Candel Therapeutics, Inc. (CADL)vs ›	$723.18M	N/A	N/A	N/A	N/A
Avalo Therapeutics, Inc. (AVTX)vs ›	$714.37M	N/A	877.08x	871.89x	871.89x
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.65M	9.07x	12.78x	12.26x	15.40x
ArriVent BioPharma, Inc. (AVBP)vs ›	$702.82M	N/A	N/A	N/A	N/A
Apnimed, Inc. (APMD)vs ›	$742.70M	N/A	N/A	N/A	N/A
Design Therapeutics, Inc. (DSGN)vs ›	$747.61M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$694.79M	N/A	501.20x	422.57x	422.57x
Wave Life Sciences Ltd. (WVE)vs ›	$693.61M	N/A	N/A	N/A	N/A
Faeth Therapeutics, Inc. (FTH)vs ›	$693.19M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics